GKOS

Glaukos Corp

Add to Watchlist

Advanced Chart

94.470

+0.52(0.553%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

94.760

Open

93.870

VWAP

94.08

Vol

678.61K

Mkt Cap

5.42B

Low

93.050

Amount

63.84M

EV/EBITDA(TTM)

Total Shares

57.35M

5.18B

EV/OCF(TTM)

P/S(TTM)

12.18

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

122.51M

+26.73%

-0.261

-6.95%

131.18M

+24.34%

-0.171

-57.26%

135.13M

+26.69%

-0.109

-50.31%

Estimates Revision

The market is revising Upward the revenue expectations for Glaukos Corporation (GKOS) for FY2025, with the revenue forecasts being adjusted by 0.75% over the past three months. During the same period, the stock price has changed by -0.02%.

Revenue Estimates for FY2025

Revise Upward

+0.75%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+6.36%

In Past 3 Month

Stock Price

Go Down

-0.02%

In Past 3 Month

13 Analyst Rating

31.61% Upside

Wall Street analysts forecast GKOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GKOS is 124.33 USD with a low forecast of 87.00 USD and a high forecast of 165.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

2 Hold

0 Sell

Strong Buy

31.61% Upside

Current: 94.470

Low

87.00

Averages

124.33

High

165.00

31.61% Upside

Current: 94.470

Low

87.00

Averages

124.33

High

165.00

BTIG

Buy

maintain

$114 -> $117

2025-07-14

Reason

BTIG

Price Target

$114 -> $117

2025-07-14

maintain

Buy

Reason

BTIG raised the firm's price target on Glaukos to $117 from $114 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 results in MedTech. Healthcare was a laggard in Q2 relative to the S&P, and early into Q3, MedTech is underperforming as fears of Medicaid cuts and hospital closures weigh on the sector following recent legislation, the analyst tells investors in a research note. The fears are likely overblown, though the earnings season is likely to offer a mixed picture as sentiment is extremely binary right now, with some companies pushing extreme valuations and others "left for dead", BTIG notes. The firm adds however that on one hand, inflation is calm, markets are at highs, and Fx has turned demonstrably favorable.

Mizuho

Anthony Petrone

Buy

Maintains

$200 → $175

2025-04-16

Reason

Mizuho

Anthony Petrone

Price Target

$200 → $175

2025-04-16

Maintains

Buy

Reason

Mizuho lowered the firm's price target on Glaukos to $175 from $200 and keeps an Outperform rating on the shares as part of a Q1 preview for the medical devices and diagnostics group. The firm views tariffs, China exposure, and the latest procedure outlook as the key themes heading into the quarter. It cut numbers preemptively.

Piper Sandler

Matt O'Brien

Buy

Maintains

$180 → $165

2025-04-15

Reason

Piper Sandler

Matt O'Brien

Price Target

$180 → $165

2025-04-15

Maintains

Buy

Reason

Truist Securities

Richard Newitter

Strong Buy

Maintains

$185 → $140

2025-04-11

Reason

Truist Securities

Richard Newitter

Price Target

$185 → $140

2025-04-11

Maintains

Strong Buy

Reason

Truist lowered the firm's price target on Glaukos to $140 from $185 and keeps a Buy rating on the shares as part of a broad research note previewing Q1 results in Medical Technology. The group's revenue and earnings are less at risk than it could be for a number of other sub-sectors, which will likely keep investors relatively interested in the space even with some tariff choppiness in the backdrop, though the firm is also bracing for cautious 2025 outlooks as companies and models will likely begin to dial-in some macro uncertainty, the analyst tells investors in a research note.

Needham

David Saxon

Strong Buy

Maintains

$149 → $176

2025-02-21

Reason

Needham

David Saxon

Price Target

$149 → $176

2025-02-21

Maintains

Strong Buy

Reason

Needham raised the firm's price target on Glaukos to $176 from $149 and keeps a Buy rating on the shares after its Q4 results. The company's iDose revenue grew sequentially to $16M and its 2025 guidance implies sales contribution of $115-120M, the analyst tells investors in a research note, adding that Glaukos is making further progress on its pipeline with Epioxa and Trio both expected to receive approval over the next 12-24 months.

Wells Fargo

Larry Biegelsen

Buy

Maintains

$153 → $160

2025-02-21

Reason

Wells Fargo

Larry Biegelsen

Price Target

$153 → $160

2025-02-21

Maintains

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Glaukos Corp (GKOS.N) is -164.68, compared to its 5-year average forward P/E of -57.75. For a more detailed relative valuation and DCF analysis to assess Glaukos Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-57.75

Current PE

-164.68

Overvalued PE

-19.41

Undervalued PE

-96.10

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-101.22

Current EV/EBITDA

-272.76

Overvalued EV/EBITDA

0.62

Undervalued EV/EBITDA

-203.06

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

11.11

Current PS

10.14

Overvalued PS

14.34

Undervalued PS

7.87